KeyBanc on the Potential Breakout Year for GLP-1 Beneficiaries West Pharmaceutical (WST) and STVN
Tweet Send to a Friend
KeyBanc analyst Paul Knight reiterated an Overweight rating and $325.00 price target on West Pharmaceutical (NYSE: WST).The analyst commented: "Eli ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
